Strs Ohio decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) by 88.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,400 shares of the company’s stock after selling 18,700 shares during the quarter. Strs Ohio’s holdings in LivaNova were worth $121,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of LIVN. State of Alaska Department of Revenue increased its holdings in shares of LivaNova by 2.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 7,666 shares of the company’s stock worth $478,000 after buying an additional 175 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in LivaNova by 29.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 787 shares of the company’s stock valued at $49,000 after purchasing an additional 180 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of LivaNova by 2.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 8,214 shares of the company’s stock worth $513,000 after purchasing an additional 188 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of LivaNova by 1.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 28,970 shares of the company’s stock valued at $1,810,000 after purchasing an additional 308 shares during the last quarter. Finally, Retirement Systems of Alabama raised its holdings in shares of LivaNova by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 159,299 shares of the company’s stock valued at $9,951,000 after buying an additional 562 shares in the last quarter. 98.89% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
LIVN has been the subject of a number of recent research reports. Barclays began coverage on shares of LivaNova in a report on Wednesday, December 21st. They issued an “equal weight” rating and a $62.00 price objective for the company. Piper Sandler decreased their price target on LivaNova from $94.00 to $84.00 in a research note on Wednesday, November 2nd. Needham & Company LLC lowered their price target on shares of LivaNova from $88.00 to $77.00 and set a “buy” rating for the company in a report on Wednesday, November 2nd. TheStreet lowered shares of LivaNova from a “c-” rating to a “d” rating in a report on Wednesday, October 19th. Finally, StockNews.com upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Monday, December 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $79.50.
LivaNova Stock Down 0.7 %
LivaNova (NASDAQ:LIVN – Get Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.01. LivaNova had a positive return on equity of 9.28% and a negative net margin of 9.14%. The company had revenue of $252.60 million during the quarter, compared to analyst estimates of $246.53 million. As a group, sell-side analysts anticipate that LivaNova PLC will post 1.73 earnings per share for the current fiscal year.
In other LivaNova news, CEO Damien Mcdonald sold 2,220 shares of the business’s stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $54.56, for a total value of $121,123.20. Following the completion of the transaction, the chief executive officer now owns 83,749 shares of the company’s stock, valued at approximately $4,569,345.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.38% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.